CMIC：2023年基因筛查项目使日本成为临床试验的新兴选择报告（英文版）

RO.ecent advances in genetic analytictechnologies like next generationsequencing(NGS)and multiplexpolymerase chain reaction (PCR) havereduced both the costs and the time needed todetect gene mutations, and have also made itpossible to develop personalized cancer treatmentsbased on the results of a genomic analysis ofindividual patients.

Taking advantage of this, japan's largestpharmaceutical contract research organization(CRO),CMlC,is participating in two importantgenetic screening